NABUMETONE-500 TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

NABUMETONE

Dostupno od:

PRO DOC LIMITEE

ATC koda:

M01AX01

INN (International ime):

NABUMETONE

Doziranje:

500MG

Farmaceutski oblik:

TABLET

Sastav:

NABUMETONE 500MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0122821001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2010-07-13

Svojstava lijeka

PRODUCT MONOGRAPH
NABUMETONE - 500
NABUMETONE TABLETS BP
500 MG
NONSTEROIDAL ANTI-INFLAMMATORY AGENT
PRO DOC LTÉE
DATE OF PREPARATION:
2925, BOUL. INDUSTRIEL
November 13, 1998
LAVAL, QUÉBEC
DATE OF REVISION:
H7L 3W9
January 14, 2009
Control #: 122225
_ _
_ _
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................................3
SUMMARY PRODUCT INFORMATION
...................................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................................3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
...........................................................................................4
ADVERSE REACTIONS
...........................................................................................................9
DRUG INTERACTIONS
..........................................................................................................12
DOSAGE AND
ADMINISTRATION.........................................................................................13
OVERDOSAGE
.......................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................13
STORAGE AND STABILITY
...................................................................................................15
DOSAGE FORMS, COMPOSITION AND
PACKAGING.........................................................15
PART II: SCIENTIFIC
INFORMATION.......................................................................................16
PHARMACEUTICAL INFORMATION
.....................................................................................16
CLINICAL
TRIALS.................................................................................